Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


510(k) review cycle stability is indicator of meaningful reviews -- CDRH staffers.

This article was originally published in The Gray Sheet

Executive Summary

FDA 510(k) AVERAGE REVIEW CYCLES STEADY AT 1.67 per submission in fiscal 1995, Joseph Levitt, Deputy Director for Regulations and Policy, Center for Devices and Radiological Health, reported Dec. 13 at the Food and Drug Law Institute Educational Conference in Washington, D.C. The average cycle figure has been essentially constant since fiscal 1991, when it was also 1.67. "We have been running consistently over the last five years about an average of 1.6 cycles, and that has not changed," Susan Alpert, director of FDA's Office of Device Evaluation said at a separate FDLI session.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts